Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Kedudukan dalam Saham #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Harga Saham
$2.65
Disegerakkan terakhir: 2024-04-03
Modal Pasaran
$115.71M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Kinnate Biopharma Inc. (KNTE)

Kategori

EPS untuk Kinnate Biopharma Inc. (KNTE)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham Kinnate Biopharma Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk Kinnate Biopharma Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH